DICE Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
400 East Jamie Court, Suite 300, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 30
Former names
DiCE Molecules Holdings, LLC (to 9/10/2021), DiCE MOLECULES HOLDINGS, LLC (to 9/10/2021)
Latest financial report
Q2 2023 - Aug 8, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3K % +20.4%
Debt-to-equity 5.87 % -12.9%
Return On Equity -22 % +9.31%
Return On Assets -20.8 % +8.58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.8M shares +25.1%
Entity Public Float 437M USD
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 47.3M shares +26.6%
Weighted Average Number of Shares Outstanding, Diluted 47.3M shares +26.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 86.7M USD +67.8%
General and Administrative Expense 32M USD +50.3%
Operating Income (Loss) -119M USD -62.7%
Net Income (Loss) Attributable to Parent -104M USD -41.5%
Earnings Per Share, Basic -2.33 USD/shares -27.6%
Earnings Per Share, Diluted -2.33 USD/shares -27.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 73.5M USD +338%
Marketable Securities, Current 455M USD +71.4%
Accounts Receivable, after Allowance for Credit Loss, Current 1.5M USD
Assets, Current 532M USD +86.9%
Property, Plant and Equipment, Net 4.44M USD +42.7%
Operating Lease, Right-of-Use Asset 12.3M USD -11%
Other Assets, Noncurrent 1.42M USD +156%
Assets 551M USD +82%
Accounts Payable, Current 3.41M USD +73.9%
Employee-related Liabilities, Current 4.26M USD +118%
Liabilities, Current 20.6M USD +70.5%
Operating Lease, Liability, Noncurrent 11M USD -12.2%
Liabilities 31.6M USD +28.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -248M USD -72.5%
Stockholders' Equity Attributable to Parent 519M USD +86.8%
Liabilities and Equity 551M USD +82%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4M USD -58.4%
Net Cash Provided by (Used in) Financing Activities 292K USD
Net Cash Provided by (Used in) Investing Activities -338M USD -605%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 73.7M USD +334%
Interest Paid, Excluding Capitalized Interest, Operating Activities 76K USD -6.17%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 43.1M USD +92%
Operating Lease, Liability 13.3M USD
Depreciation 244K USD +61.6%
Payments to Acquire Property, Plant, and Equipment 202K USD -47.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -103M USD -36.5%
Lessee, Operating Lease, Liability, to be Paid 17.9M USD -11.9%
Property, Plant and Equipment, Gross 6.25M USD +28.3%
Operating Lease, Liability, Current 1.53M USD +16.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.74M USD +2.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.67M USD +9.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.64M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.81M USD +2.78%
Deferred Tax Assets, Operating Loss Carryforwards 17.3M USD +28.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.43M USD +71.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.89M USD +2.74%
Additional Paid in Capital 767M USD +81.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 4.39M USD -16.9%
Interest Expense 268K USD +38.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%